Related Experiment Video
Updated: Feb 12, 2026

Generation of Self-assembled Vascularized Human Skin Equivalents
Published on: February 12, 2021
Equivalent Recombinant Human Insulin Preparations and their Place in Therapy
Juergen Sandow1, Wolfgang Landgraf2, Reinhard Becker3
1Professor, Centre of Pharmacology, Johann-Wolfgang-Goethe University, Frankfurt-Main, Germany.
Abstract:
Recombinant human insulin was one of the first products of biotechnology. It was developed in response to the need for a consistent and sufficient worldwide supply. Recombinant human insulin replaced the animal insulins and semisynthetic insulins obtained by modification of animal insulins. Bioequivalence studies were required for regulatory approval. Three reference products were independently established during these procedures: Humulin® (Eli Lilly and Co), Novolin® (NovoNordisk) and Insuman® (Sanofi). Numerous brand names have been used during the commercial development of recombinant human insulin formulations. In this review, three current brand names are used for consistent identification. Human insulin for Humulin and Insuman are produced by fermentation in bacteria (Escherichia coli) and for Novolin in yeast (Saccharomyces cerevisiae). The bioequivalence of recombinant human insulin products was investigated in euglycaemic clamp studies. An overview of such bioequivalence studies is provided here. This paper will consider the relevance of human insulin formulations today and their place in therapy.
Related Concept Videos
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Recombinant DNA
Pharmaceutical Equivalents
Equivalent Capacitance
The following strategies are adopted to calculate...
Equivalent Capacitance
Thévenin Equivalent Circuits

